B. Riley lowered the firm’s price target on Wave Life Sciences (WVE) to $19 from $22 and keeps a Buy rating on the shares. The firm cites FDA timeline risk for the target cut, which it notes is not unique to Wave Life.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wedbush starts RNA-focused standout Wave Life Sciences with an Outperform
- Wave Life Sciences initiated with an Outperform at Wedbush
- Wave Life Sciences’ Promising DMD Treatment Justifies Buy Rating Amid Positive Phase 2 Study Results
- Wave Life Sciences: Buy Rating Affirmed on Promising Clinical Results and Strategic Growth Plans
- Wave Life Sciences Reports Positive Phase 2 Trial Results